|
|
Legal status
Patent in force
| (51) | INT.CL. | C07K 14/54 | (2006.01) |
| C07K 16/24 | (2006.01) |
| (11) | Number of the document | 2294083 |
| (13) | Kind of document | T |
| (96) | European patent application number | 09735498.9 |
| Date of filing the European patent application | 2009-04-22 | |
| (97) | Date of publication of the European application | 2011-03-16 |
| (45) | Date of publication and mention of the grant of the patent | 2015-07-29 |
| (46) | Date of publication of the claims translation | 2015-11-25 |
| (86) | Number | PCT/GB2009/001026 |
| Date | 2009-04-22 |
| (87) | Number | WO 2009/130459 |
| Date | 2009-10-29 |
| (30) | Number | Date | Country code |
| 0807413 | 2008-04-23 | GB |
| (72) |
CESKA, Thomas, Allen, GB
HENRY, Alistair, James, GB
SHI, Jijye, GB
|
| (73) |
UCB Biopharma SPRL,
Allée de la Recherche 60, 1070 Brussels,
BE
|
| (74) |
Jurga PETNIŪNAITĖ,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
| (54) | IL-17A ir IL-17F epitopai ir jų atžvilgiu specifiniai antikūnai |
| EPITOPES OF IL-17A AND IL-17F AND ANTIBODIES SPECIFIC THERETO |
| Payment date | Validity (years) | Amount | |
| 2026-03-19 | 18 | 347.00 EUR |
| 2027-04-22 |